---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-075268"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:22:32.928554+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones

## Summary
- Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.
- Cash and equivalents $11.6M; plus $41.9M in NIA grant funds; runway into Q2 2026.
- Surpassed 50% enrollment in Phase 2 START study of zervimesine in early Alzheimer's.
- EOP2 meeting with FDA held; breakthrough designation application for zervimesine in DLB pending.
- Positive Phase 2 dry AMD data showed 28.6% reduction in GA lesion growth at 18 months.

## SEC filing metadata
- accession: 0001104659-25-075268
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925075268/0001104659-25-075268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925075268/tm2522152d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-075268
- JSON: https://secwatch.observer/filing/0001104659-25-075268.json
- Plain text: https://secwatch.observer/filing/0001104659-25-075268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.